GUB-014295

Roche has entered into a $5.3 billion collaboration with Zealand Pharma to co-develop petrelintide, a promising amylin analog for obesity treatment, both as monotherapy and in combination with Roche's incretin asset CT-388.

The first quarter of 2025 witnessed significant biotech partnership activity, with Eli Lilly, AstraZeneca, and Novo Nordisk emerging as top collaborators in deals worth billions across small molecules, antibodies, and RNA therapeutics.

AbbVie makes its strategic entry into the obesity therapeutics market through a $350 million upfront licensing agreement with Danish biotech Gubra for their amylin analog GUB014295.

The anti-obesity drug landscape is evolving with the introduction of breakthrough treatments like Semaglutide and Tirzepatide, alongside the development of innovative monotherapies, combination therapies, and emerging injectable pharmacotherapies. The focus is also shifting towards oral drug formulations and addressing sarcopenia in obesity treatment. Preclinical research and clinical trials continue to play a crucial role in advancing obesity therapeutics.